The key now is get the distribution of the new shares behind us and the presentations in the next 2 weeks hopefully give further updates on how the 907 expansions are progressing. Then off the top of my head, we wait for Q1 results and updates; and then ASCO. During that time I expect a methodical rise in PPS in expectations of very good news at ASCO. Pretty cut and dry. One wildcard during that time I'd like to see happen is that Roche resumes the IPF\Erivedge trial. That could be very large for us down the road. Very big population. For the T/A inclined people there are obvious resistance areas along the way. We briefly touched the one premarket- the 3.60 area the other day; then the gap to fill @ 3.85; and then another in the 4.4-4.6 area.
News 
Market Data 
Discover 
